Soligenix (NASDAQ: SNGX) — Company Overview, News & Financial Data
Soligenix (NASDAQ:SNGX) is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an
Soligenix
Soligenix (NASDAQ:SNGX) is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. With a robust research pipeline, the firm is currently advancing multiple projects across two distinct areas: BioTherapeutics and Vaccines/BioDefense. Among its notable undertakms are innovative treatments for conditions such as cutaneous T-cell lymphoma, pediatric Crohn’s disease, and acute radiation syndrome. Soligenix's objective is to harness its proprietary technologies and scientific expertise to provide breakthrough therapies for serious health conditions, striving to improve patient outcomes and quality of life.
Snapshot
Operations
Products and/or services of Soligenix
- HyBryte™, a treatment for cutaneous T-cell lymphoma, utilizing synthetic hypericin activated by light therapy.
- SGX943, a therapeutic for treating melioidosis, aims to enhance innate immunity to combat bacterial infections.
- SGX203, a pediatric Crohn's disease treatment, is designed to release budesonide throughout the small intestine and colon.
- ThermoVax®, a vaccine heat stabilization technology, enhancing the stability of vaccines for easier storage and transportation.
- RiVax®, a vaccine against ricin toxin exposure, incorporating heat stabilization for enhanced safety and effectiveness.
- OrbeShield®, aimed at treating gastrointestinal acute radiation syndrome, focuses on mitigating radiation damage to the intestines.
Soligenix executive team
- Christopher J. SchaberChairman of the Board of Directors, CEO & President
- Jonathan L. GuarinoSenior VP, CFO & Corporate Secretary
- Oreola DoniniSenior VP & Chief Scientific Officer
- Adam T. RumageSenior VP of Project Management & Regulatory Affairs
Key financials
Reported results for Soligenix, in USD.
- Market cap
- 7.9M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -11.8M | -11.1M | |
| 119.4K | -9.4M | -8.3M | |
| 839.4K | -7.7M | -6.1M | |
| 250K | -14.2M | -13.8M |